Home Management of the Device Detected Atrial Fibrillation during COVID-19 Pandemic: A Case Report

Authors

  • Idaliya Rakhimova Department of Cardiology and Interventional Arrhythmology, Semey Medical University, Kazakhstan
  • Talgat Khaibullin Department of Cardiology and Interventional Arrhythmology, Semey Medical University, Kazakhstan
  • Yerbol Smail Department of Cardiology and Interventional Arrhythmology, Semey Medical University, Kazakhstan
  • Zhanar Urazalina Department of Cardiology and Interventional Arrhythmology, Semey Medical University, Kazakhstan
  • Vitalii Koval`chuk Rehabilitation Centre, Hospital No 38 named after N.I. Semashko, St. Petersburg, Russia
  • Ayan Abdrakhmanov Department of Interventional Arrhythmology, National Scientific Cardiac Surgery Center, Astana, Kazakhstan

DOI:

https://doi.org/10.3889/oamjms.2021.6687

Keywords:

Stroke, Atrial fibrillation, Remote monitoring, Cardiovascular implantable electronic device, Coronavirus disease –2019

Abstract

BACKGROUND: Patients with heart failure (HF) and implanted heart devices constitute a vulnerable category during the coronavirus disease –2019 (COVID-19) pandemic. The remote monitoring function allows the physician to detect atrial fibrillation (AF) in these patients and to prevent thromboembolic complications by prescribing anticoagulants. Under quarantine conditions, such patients can receive fully remote consultation and treatment, which will protect them from the risk of infection, and also reduce the burden on medical institutions.

CASE REPORT: A 56-year-old man presented to the clinic with shortness of breath when climbing the second floor, moderate non-specific fatigue, general weakness, and a decrease in exercise tolerance. The patient received standard treatment for HF for at least 3 months (ACEI, beta blockers, MR antagonists, and loop diuretics) in individually selected adequate doses. ECG on admission showed a QRS of 150 ms, left bundle branch block (LBBB). Echo showed dilatation of all heart chambers, diffuse hypokinesis of the walls with akinesis of the apical, middle anterior LV segments, as well as hypokinesis of the basal, middle apical, and anterior septal segment of the LV. The ejection fraction was reduced to 35%. RV function is reduced. After a detailed discussion with the team, it was decided to do implantation of a cardioverter-defibrillator with resynchronization function, equipped with remote monitoring (Biotronik, and Home monitoring). Date of implantation is June 19, 2014. Due to the fact that the patient was connected to the remote monitoring system, May 5, 2020, he was diagnosed with asymptomatic AF. The episode lasted 1 min 22 s. On the following days of monitoring, episodes of AF were also recorded. The duration of the episodes ranged from a few seconds to 12 h/day. The patient received a doctor’s consultation through phone call, his risk of stroke was four when assessed using the CHA2DS2VASc scale. In treatment, it was recommended to add antiarrhythmic drugs (amiodarone 600 mg a day) and oral anticoagulants (rivaroxaban 20 mg × 1 time/day). Later, periodic IEGM showed absence of AF.

CONCLUSION: In the context of the COVID-19 pandemic, health-care providers should rethink their approach to managing patients with implanted heart devices. Modern cardiovascular implantable electronic devices allow the physician to monitor the status of patients and immediately respond to situations requiring a change in treatment. Consultations can be carried out completely online.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Dilaveris PE, Kennedy HL. Silent atrial fibrillation: Epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017;40(6):413-8. http://doi.org/10.1002/clc.22667 PMid:28273368

Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United States from 1997 through 2004: A population-based analysis. J Gen Intern Med. 2008;23(Suppl 1):13-9. http://doi.org/10.1007/s11606-007-0392-0 PMid:18095038

Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: Calendar year 2009-a world society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34(8):1013-27. http://doi.org/10.1111/j.1540-8159.2011.03150.x PMid:21707667

Yegorov S, Goremykina M, Ivanova R, Good SV, Babenko D, Shevtsov A, et al. Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study. Lancet Reg Health Eur. 2021;4:100096. http://doi.org/10.1016/j.lanepe.2021.100096 PMid:33880458

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr., et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;139:2502-12. http://doi.org/10.1161/CIRCULATIONAHA.118.038988

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The task force for the management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC Endorsed by the European stroke organization (ESO). Eur Heart J. 2016;38:2893-962. http://doi.org/10.1093/eurheartj/ehw210 PMid:27567408

Zacà V, Marcucci R, Parodi G, Limbruno U, Notarstefano P, Pieragnoli P, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6):840-54. http://doi.org/10.1093/europace/euu357 PMid:25712980

NICE Guidance 106: Chronic Heart Failure in Adults: Diagnosis and Management; 2018. Available from: https://www.nice.org.uk/guidance/ng106. [Last accessed on 2020 Mar 30].

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091. http://doi.org/10.1136/bmj.m1295 PMid:32234718

Cowie MR, Sarkar S, Koehler J, Whellan DJ, Crossley GH, Tang WH, et al. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J. 2013;34(31):2472-80. http://doi.org/10.1093/eurheartj/eht083 PMid:23513212

Noseworthy PA, Kaufman ES, Chen LY, Chung MK, Elkind MS, Joglar JA, et al. Subclinical and device-detected atrial fibrillation: Pondering the knowledge gap: A scientific statement from the American heart association. Circulation. 2019;140(25):e944-63. http://doi.org/10.1161/CIR.0000000000000740 PMid:31694402

Van Gelder IC, Healey JS, Crijns HJ, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339-44. http://doi.org/10.1093/eurheartj/ehx042 PMid:28329139

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ Arrhythm Electrophysiol. 2009;2(5):474-80. http://doi.org/10.1161/CIRCEP.109.849638 PMid:19843914

Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, et al. Practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation. Circulation. 2019;139(22):2502-12. http://doi.org/10.1161/CIRCULATIONAHA.118.038988 PMid:30880434

Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45. http://doi.org/10.1016/j.ahj.2017.04.008 PMid:28625370

Yang Y, Xu F, Tong J, Cai L, Jiang W, Sheng X, et al. Rationale and design of the evaluation of oral anticoagulation for reduction of thrombo-embolism in Chinese patients with device-detected subclinical atrial fibrillation (ART-CAF) trial: An open-label registry-based clinical trial. Cardiovasc Drugs Ther. 2018;32(4):389-96. http://doi.org/10.1007/s10557-018-6807-9 PMid:30027309

Downloads

Published

2021-09-20

How to Cite

1.
Rakhimova I, Khaibullin T, Smail Y, Urazalina Z, Koval`chuk V, Abdrakhmanov A. Home Management of the Device Detected Atrial Fibrillation during COVID-19 Pandemic: A Case Report. Open Access Maced J Med Sci [Internet]. 2021 Sep. 20 [cited 2022 Jan. 24];9(C):170-3. Available from: https://oamjms.eu/index.php/mjms/article/view/6687

Issue

Section

Case Report in Internal Medicine

Categories